Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | F11 | P03951 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.46 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.46 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.46 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.46 |
| ▸ | MGLL | Q99685 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 4/20 | 0.46 |
| ▸ | MMP9 | P14780 | 4/20 | 0.46 |
| ▸ | MMP8 | P22894 | 4/20 | 0.46 |
| ▸ | MMP13 | P45452 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1082689 | 0.87 | GRIA1 (0.56) | CA12CA9F11ALDH1A1GRIA1 | |
| SCHEMBL1082745 | 0.87 | PGR (0.59) | MMP2MMP9MMP8MMP13NPC1 | |
| SCHEMBL4552802 | 0.78 | CA12 (0.57) | CA12CA9F11NPC1HTT | |
| SCHEMBL4427396 | 0.78 | GRIA1 (0.58) | CA12CA9ALDH1A1GRIA1GRIA2 | |
| SCHEMBL10117949 | 0.78 | ALDH1A1 (0.55) | ALDH1A1GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL28534328 | 0.78 | ALDH1A1 (0.47) | ALDH1A1GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL4290533 | 0.77 | CA12 (0.53) | CA12CA9F11MGLL | |
| SCHEMBL16573987 | 0.77 | CA12 (0.73) | CA12CA9F11ALDH1A1NPC1 | |
| SCHEMBL2324527 | 0.77 | F11 (0.73) | CA12CA9F11ALDH1A1MGLL | |
| SCHEMBL7703280 | 0.76 | CA12 (0.50) | CA12CA9ALDH1A1MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875624-B2 | administering a cancer patient 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one in the treatment of disorders relating to cell adhesion and metastatic processes; for monitoring the effects of drug by measuring the levels of ICAM, VCAM, or E-selectin in the patient | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2011-01-25 | — | — | US | disclosed |
| US-20050239825-A1 | Modulation of inflammatory and metastatic processes | CHIRON CORPORATION | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239825-A1 | Modulation of inflammatory and metastatic processes | VCAM1, EPCAM, ICAM1 | CA12 268/4885CA9 777/4885F11 611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.